# What Hims announced for Peptides+ Canonical: https://europeanpeptideshop.com/blog/hims-peptides-plus-announcement/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page Hims & Hers previewed Peptides+ on October 29, 2026. The company described a forthcoming specialty and invited people to join a list. That announcement is useful industry news, but a preview should be distinguished from confirmation that every named therapy is already available. [1](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) ## What did the company say it planned to offer? The statement names sermorelin, glutathione, B12, NAD+ and L-carnitine as planned offerings, with BPC-157 and TB-500 to follow when allowable. It describes independent providers, licensed pharmacies and a US-based peptide manufacturing facility. These are the company's descriptions of its plans. [1](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) Part of the announcement | How to read it Peptides+ preview and signup list | An announced service, not proof of complete rollout Named initial offerings | A company plan that needs an availability check BPC-157 and TB-500 | Conditional additions in the statement [1](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) ## Why does the timing matter? The preview followed the HHS peptide policy announcement. The corresponding Federal Register notice was published October 30 and describes a draft enforcement approach during development of the 503A bulk-substances list. [2](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm) A business can announce its intended response to a policy before every legal, operational or clinical detail has settled. Reading the corporate statement and the government document side by side prevents one from being mistaken for the other. ## Does a compounded offering mean FDA approval? FDA distinguishes compounded drugs from approved medicines and approved generics. Compounded drugs do not receive FDA's premarket review of safety, effectiveness and quality. The fact that a service is offered through a pharmacy does not transform it into an FDA-approved drug. [3](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) The useful comparison is therefore between specific products, services and evidence. A brand name, molecule name, prescribing arrangement and manufacturing claim each answers a different question. None should substitute for the others. ## What remains to be checked? Hims acknowledges limited published evidence and uncertainty around its plans. Its statement does not establish that every proposed benefit has been demonstrated in a controlled trial. [1](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) For a later update, check which offering actually launched, its eligibility and availability, and the source supporting each clinical claim. Keep the date of the announcement distinct from a launch date. A changed signup page alone would not establish a new efficacy finding. ## Why this belongs in peptide industry coverage The announcement provides a concrete example of how telehealth businesses are responding to policy discussions. Following that development can help readers understand the market without treating a company's commercial expectations as clinical evidence. ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Hims & Hers: Expanding Safe Access to Peptides, October 29, 2026](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) - [Federal Register: HHS draft policy notice](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm) - [FDA: Compounding questions and answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) ## More articles Research news · 3 min read ## [The Lilly and Hims access agreement](https://europeanpeptideshop.com/blog/lilly-hims-zepbound-foundayo-access-agreement/) What the November 2026 Lilly: Hims agreement changes for Zepbound and Foundayo, and how branded GLP-1 access differs from Peptides+ and compounded drugs. 8 November 2026 Research news · 2 min read ## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/) Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them. 8 November 2026 Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026